Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial
Nick Freemantle, Patrick Mollon, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Robin Kate Kelley, Ari David Baron, Fawzi Benzaghou, Milan Mangeshkar, Ghassan K. Abou‐Alfa
Topics & Concepts
CabozantinibMedicinePlaceboQuality of life (healthcare)SorafenibConfidence intervalQuality-adjusted life yearPopulationHepatocellular carcinomaInternal medicineCost effectivenessCancerAlternative medicineEnvironmental healthRisk analysis (engineering)PathologyNursingHepatocellular Carcinoma Treatment and PrognosisEconomic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life